The Shares of the leading pharmaceutical company hit a 20 % upper circuit on Tuesday’s first half-session on the National Stock Exchange after the company received marketing approval from the European Medicines Agency for its antibiotic drug Exblifeb.
On Tuesday’s trade, Orchid Pharma Ltd shares hit a 20% upper circuit to a 52-week high price of ₹859.40 a share from the previous close price and the company has a market capitalization of ₹4,359 crore.
As per reports, The company’s Exblifeb drug received approval from the European Medicines Agency for marketing authorization. Exblifep incorporates Enmetazobactam the first drug invented in India to have achieved this landmark.
The drug is used in the treatment of complicated Urinary Tract Infections (cUTI), pneumonia,and bacteremia caused by extended-spectrum beta-lactamase-producing pathogens.
The company’s revenue climbed by 21 percent year on year, rising from ₹ 165 crore in Q2FY23 to ₹ 199 crore in Q2FY24. During the same period, net profit increased from a loss of ₹ 5 crore to a profit of ₹ 20 crore.
In the recent financial year, the company reported a net profit margin of 7.27 percent and an operating margin of 7.24 percent.
Orchid Pharma shares have given returns of 51% in the last six months and also delivered multibagger returns of 159% in a year. Such that, A shareholder investment of ₹1 lakh in the company a year ago, would be worth ₹2.59 lakhs.
As per the recent shareholding pattern, the company’s promoters hold 69.84 percent stake, while domestic institutional investors hold 14.51 percent and retail investors hold an 11.52 percent stake in the company.
Orchid Pharma is a pharmaceutical company engaged in the development and manufacture of active pharmaceutical ingredients (APIs) and finished dosage forms.
Some of the company’s notable clients include Sanofi, Sun Pharma, Pfizer, Mylan, etc. The top 10 clients of Orchid contribute to 57% of the total revenues geographically.
Written by Omkar Chitnis
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
